New Market Report: Hepatitis C Therapeutics in Asia-Pacific Markets to 2023

22.11.2017 14:49:36 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape

- This report might qualify for up to a 30% DISCOUNT if purchased before the end of 2017
- More details at ..

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75


million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma. The APAC region has diverse HCV epidemiology, with prevalence ranging from 0.1% to 4.7%, and a unique genotype (GT) distribution. Acute HCV infection is usually asymptomatic, and 15-45% of people spontaneously clear the virus within six months of infection without any treatment, while the remaining 55-85% develop chronic HCV infection.

The hepatitis C market is currently dominated by high-performance regimens comprising new-generation DAAs. The treatment algorithms have shifted away rapidly from interferon-based therapies, and towards interferon-free DAA combination therapies that can cure most patients in as little as eight to 12 weeks, without ribavirin. In the highly competitive hepatitis C treatment landscape, where new combination therapies match each other closely in terms of safety and efficacy, one key differential is patient segment coverage. A number of factors that have conventionally been used to predict treatment outcome, including HCV genotypes, previous treatment history, and a patient's liver and kidney conditions, are also used to define target patient populations for new therapies.

The late-stage hepatitis C pipeline is predominantly composed of DAA regimens targeting HCV NS5A, NS5B polymerase, and NS3/4A protease. The most advanced of the promising pipeline agents are Gilead's sofosbuvir/velpatasvir/voxilaprevir and AbbVie's glecaprevir/pibrentasvir, which have been studied in Phase III clinical trials. Due to the highly effective late-stage pipeline drugs and marketed products, developers of HCV NS5A, NS5B polymerase and NS3/4A protease in earlier stages of clinical development are not aiming to dominate the market, but rather to earn a place as a 'me too' product.


The hepatitis C Asia-Pacific market will be valued at $8.31 billion in 2023, growing from $5.38 billion in 2016 at a CAGR of 6.4%.

* How will pan-genotypic therapies such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir contribute to growth?
* What effect will the patent expiration of branded therapies have on market value?

The hepatitis C pipeline contains a range of molecule types and molecular targets, including those that are well established in hepatitis C, and novel target therapies.

* What are the common targets and mechanisms of action of pipeline therapies?
* Will the pipeline therapies fulfill the unmet needs of the hepatitis C market?
* What implications will the increased focus on pan-genotypic therapies have on the future of hepatitis C treatment?

Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

* How have the late-stage therapies performed in clinical trials?
* How will the approval of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, which hold a key advantage in terms of reducing the treatment duration, affect the competitive landscape, with no therapy currently available to address this unmet need?

The market forecasts indicate that China and Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

* What will be the impact of available therapies with high cure rates on prevalence?
* How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
* Which countries are in the best situation currently for the eradication of HCV?

Various drivers and barriers will influence the hepatitis C market over the forecast period.

* What are the barriers that will limit the uptake of available and upcoming therapies in the assessed countries?
* Which factors are most likely to drive the market in these countries?

Licensing deals are the most common form of strategic alliance in hepatitis C, with total deal values ranging from under $10m to over $1.5 billion.

Browse our complete collection of Pharmaceuticals research reports at ..

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Bill Thompson
Phone: 1.413.485.7001


Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact We are not able to assist you. disclaims content contained in this article. is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Contact Us